Sunshine Biopharma (SBFM) EBT (2011 - 2026)

Sunshine Biopharma (SBFM) has reported EBT for 15 consecutive years, with -$1.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 21.01% year-over-year to -$1.6 million; the trailing twelve-month figure through Jun 2026 stood at -$5.6 million (up 14.03% YoY), and the FY2025 full-year result was -$6.0 million, down 10.89% from the prior year.
• EBT slipped to -$1.6 million in Q2 2026 per SBFM's latest filing, from -$1.2 million in the prior quarter.
• Across five years, EBT topped out at -$538872.0 in Q2 2022 and bottomed at -$23.3 million in Q4 2022.
• Historically, EBT has averaged -$2.5 million across 5 years, with a median of -$1.2 million in 2022.
• The sharpest annual moves came in 2022 and 2023: EBT sank 3589.5% in 2022, then soared 95.58% in 2023.
• Over 5 years, EBT stood at -$23.3 million in 2022, then jumped by 95.58% to -$1.0 million in 2023, then sank by 122.09% to -$2.3 million in 2024, then grew by 24.24% to -$1.7 million in 2025, then climbed by 9.73% to -$1.6 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$1.6 million, -$1.2 million, and -$1.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.